{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:41:20Z","timestamp":1789011680784,"version":"build-2803163510"},"reference-count":36,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte\u2212 mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1\/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL\/6 (B6)\u21d2CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, when used either prophylactically or therapeutically. RUX suppressed the infiltration, proliferation, and activation of effector T cells in the bone marrow and mitigated Fas-mediated apoptotic destruction of target hematopoietic cells. Similar effects were obtained when Rux-chow was fed to C.B10 mice in a minor histocompatibility antigen mismatched (B6\u21d2C.B10) AA model. RUX only modestly suppressed lymphoid and erythroid hematopoiesis in normal and irradiated CByB6F1 mice. Our data support clinical trials of JAK\/STAT inhibitors in human AA and other immune bone marrow failure syndromes.<\/jats:p>","DOI":"10.1182\/blood.2022015898","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T21:09:26Z","timestamp":1663794566000},"page":"72-89","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of JAK1\/2 inhibition in murine immune bone marrow failure"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-5926","authenticated-orcid":false,"given":"Emma M.","family":"Groarke","sequence":"first","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8018-2366","authenticated-orcid":false,"given":"Xingmin","family":"Feng","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-9920","authenticated-orcid":false,"given":"Nidhi","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash Lee","family":"Manley","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-0819","authenticated-orcid":false,"given":"Zhijie","family":"Wu","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouguo","family":"Gao","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-7701","authenticated-orcid":false,"given":"Bhavisha A.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Chen","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S.","family":"Young","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2023082419243785100_bib1","doi-asserted-by":"crossref","first-page":"101276","DOI":"10.1016\/j.beha.2021.101276","article-title":"Immunologic effects on the haematopoietic stem cell in marrow failure","volume":"34","author":"Patel","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"26","key":"2023082419243785100_bib2","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2018-05-844928","article-title":"Macrophage TNF-\u03b1 licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anemia","volume":"132","author":"Sun","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2023082419243785100_bib3","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2014-01-549527","article-title":"IFN-\u03b3 causes aplastic anemia by altering hematopoietic stem\/progenitor cell composition and disrupting lineage differentiation","volume":"124","author":"Lin","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023082419243785100_bib4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2023082419243785100_bib5","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023082419243785100_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17474086.2019.1645003","article-title":"Management of aplastic anemia after failure of frontline immunosuppression","volume":"12","author":"Pierri","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"2023082419243785100_bib7","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023082419243785100_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2011-05-352328","article-title":"Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia","volume":"119","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2023082419243785100_bib9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023082419243785100_bib10","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/bloodadvances.2020001657","article-title":"Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias","volume":"4","author":"Fan","year":"2020","journal-title":"Blood Adv"},{"key":"2023082419243785100_bib11","doi-asserted-by":"crossref","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"issue":"24","key":"2023082419243785100_bib12","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2023082419243785100_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"key":"2023082419243785100_bib14","doi-asserted-by":"crossref","first-page":"650295","DOI":"10.3389\/fphar.2021.650295","article-title":"Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome","volume":"12","author":"Huarte","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"2023082419243785100_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.stem.2013.05.014","article-title":"SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors","volume":"13","author":"Oguro","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2023082419243785100_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control bloodproduction in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"4","key":"2023082419243785100_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.V85.4.1006.bloodjournal8541006","article-title":"Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in\u00a0vivo expansion of stem cell phenotype but not function","volume":"85","author":"Spangrude","year":"1995","journal-title":"Blood"},{"issue":"24","key":"2023082419243785100_bib18","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2015-06-652453","article-title":"IFN-gamma-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023082419243785100_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20131128","article-title":"High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias","volume":"211","author":"Shin","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"2023082419243785100_bib20","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1084\/jem.20112615","article-title":"Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia","volume":"210","author":"Roderick","year":"2013","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"2023082419243785100_bib21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3324\/haematol.2017.163675","article-title":"Rapamycin is highly effective in murine models of immune-mediated bone marrow failure","volume":"102","author":"Feng","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2023082419243785100_bib22","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/s41375-021-01219-z","article-title":"CCR5 maintains macrophages in the bone marrow and drives hematopoietic failure in a mouse model of severe aplastic anemia","volume":"35","author":"Seyfried","year":"2021","journal-title":"Leukemia"},{"issue":"14","key":"2023082419243785100_bib23","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2023082419243785100_bib24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41375-021-01231-3","article-title":"Somatic mutations in lymphocytes in\u00a0patients with immune-mediated aplastic\u00a0anemia","volume":"35","author":"Lundgren","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023082419243785100_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medj.2021.12.003","article-title":"JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia","volume":"3","author":"Rosenberg","year":"2022","journal-title":"Med"},{"issue":"1","key":"2023082419243785100_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2023082419243785100_bib27","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023082419243785100_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023082419243785100_bib29","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023082419243785100_bib30","article-title":"IFN-\u03b3 inhibitors and ruxolitinib therapy for acquired severe aplastic anemia in an ex-vivo model [abstract]","volume":"138","author":"Schaefer","year":"2021","journal-title":"Blood"},{"key":"2023082419243785100_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.leukres.2018.09.004","article-title":"Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation","volume":"73","author":"Abaza","year":"2018","journal-title":"Leuk Res"},{"issue":"11","key":"2023082419243785100_bib32","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2009-06-225375","article-title":"High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up","volume":"115","author":"Brodsky","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2023082419243785100_bib33","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","article-title":"Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?","volume":"131","author":"Giammarco","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023082419243785100_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419243785100_bib35","article-title":"Efficacy and safety of eltrombopag combined with cyclosporine as first-line therapy in adults with severe acquired aplastic anemia: results of the interventional phase 2 single-arm soar study [abstract]","volume":"138","author":"Vallejo","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023082419243785100_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.exphem.2004.08.006","article-title":"A mouse model\u00a0of lymphocyte infusion-induced bone marrow failure","volume":"32","author":"Bloom","year":"2004","journal-title":"Exp Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/1\/72\/2073355\/blood_bld-2022-015898-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/1\/72\/2073355\/blood_bld-2022-015898-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:25:28Z","timestamp":1692905128000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/1\/72\/486676\/Efficacy-of-JAK1-2-inhibition-in-murine-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015898","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}